Please check your internet connection and try again.
# Piperacillin/Tazobactam
## Overview
Piperacillin is a broad-spectrum penicillin antibiotic. Tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by certain bacterial beta-lactamases, thereby extending its spectrum of activity to include many gram-negative and anaerobic bacteria. It is available in fixed combinations, typically 4.5g (piperacillin 4g/tazobactam 0.5g) or 3.375g (piperacillin 3g/tazobactam 0.375g).
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin-structure infections
* Community-acquired pneumonia
* Hospital-acquired pneumonia
* Nosocomial pneumonia
* Febrile neutropenia (empiric treatment)
## Adult Dosing
* **Standard dose:** 3.375 grams every 6 hours intravenously (IV) or 4.5 grams every 6 or 8 hours IV.
* **Maximum dose:** Dosing is typically based on the piperacillin component. Common higher doses are 4.5 grams every 6 hours or every 8 hours. Higher doses may be used for more severe infections or in specific situations based on local protocols.
## Pediatric Dosing
* **Children < 2 years:** Dosing is based on piperacillin weight. A common regimen is 100 mg piperacillin/12.5 mg tazobactam per kg per dose every 6 hours IV.
* **Children ≥ 2 years with febrile neutropenia:** 100 mg piperacillin/12.5 mg tazobactam per kg per dose every 6 hours IV, not to exceed 4.5 grams per dose.
* **Children with cystic fibrosis:** Higher doses may be utilized based on institutional protocols.
* **Infants < 1 year:** Limited data, use with caution. Dosing should be individualized and guided by institutional protocols and clinical response.
## Dose Adjustments
* **Renal impairment (CrCl ≤ 40 mL/min):** Reduce the dose frequency. For standard regimens (e.g., 3.375g q6h), administer every 8 hours. For higher frequency regimens (e.g., 4.5g q6h), administer every 8 hours. If CrCl is between 20-40 mL/min, administer every 8 hours. If CrCl < 20 mL/min, administer every 12 hours. Hemodialysis requires dosing every 12 hours and an additional dose after each dialysis session. Dose adjustments are based on piperacillin.
* **Hepatic impairment:** No dose adjustment is typically needed.
## Contraindications
* Known severe hypersensitivity to piperacillin, tazobactam, other penicillin antibiotics, or any component of the formulation.
* History of cholestatic jaundice or hepatic dysfunction associated with piperacillin/tazobactam therapy.
## Adverse Effects
* **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, fever, injection site reactions.
* **Serious:** Hypersensitivity reactions (including anaphylaxis), Clostridioides difficile-associated diarrhea (CDAD), seizures (especially with high doses or renal impairment), hematologic effects (neutropenia, thrombocytopenia, eosinophilia), liver enzyme elevations, interstitial nephritis.
## Key Drug Interactions
* **Probenecid:** May increase and prolong serum concentrations of piperacillin and tazobactam.
* **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Warfarin:** Piperacillin may decrease the effect of warfarin; monitor INR closely.
* **Methotrexate:** Piperacillin may decrease methotrexate clearance; monitor methotrexate levels.
* **Bacteriostatic agents (e.g., tetracyclines, chloramphenicol):** May antagonize the effect of penicillins.
## Monitoring
* **Renal function:** Especially in patients with pre-existing renal impairment or those receiving other nephrotoxic agents.
* **Liver function tests:** Baseline and periodic monitoring may be considered.
* **Complete blood count (CBC):** Monitor for hematologic changes, especially with prolonged therapy.
* **Signs and symptoms of hypersensitivity reactions.**
* **Signs and symptoms of CDAD.**
* **Clinical signs of infection:** Monitor for improvement or lack thereof.
## Clinical Pearls
* Piperacillin/tazobactam is a broad-spectrum agent often used empirically for serious infections, particularly those involving gram-negative rods and anaerobes.
* Dosing frequency (6 vs. 8 hours) may depend on the severity of infection, institutional protocols, and patient-specific factors. Continuous infusion can also be considered to optimize exposure, especially in critically ill patients, and often utilizes higher daily doses.
* Due to the risk of seizure activity, caution is advised in patients with a history of seizures, CNS disorders, or those receiving high doses or with significant renal impairment.
* Reconstituted solutions should be used within specified timeframes, and stability varies with diluent.
***
*Disclaimer: This information is intended for clinical pharmacy professionals and is not a substitute for current prescribing information. Always consult the official drug monograph and institutional guidelines before making any dosing or treatment decisions.*
